trial

Janssen - Glucose Regulation/Risp/Olanz

NCTId NCT00205738
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 120 (actual)
Sponsored by Washington University School of Medicine
Primary completion 2006-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
120 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2000-07
Primary completion
2006-10
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Olanzapine

Sponsors

Washington University School of MedicineLead Sponsor
Janssen, L.P. - Investigator Initiated Studies ProgramCollaborator

Investigators

1
John W. Newcomer, M.D.Principal Investigator

Sites

1 total
St Louis, United States

Facts & assertions

4 sourced
Enrollment
120
Phase
NA
Primary Completion Date
2006-10
Status
COMPLETED
relationships
The graph out of here
drug
Olanzapine
drug
lead_sponsor
Washington University School of Medicine
company
collaborator
Janssen, L.P. - Investigator Initiated Studies Program
company
indication
Schizophrenia
indication
Schizophrenia
indication
Type 2 Diabetes Mellitus
indication
investigator
John W. Newcomer, M.D.
person